Drugs / Ivabradine
last change Jun 2026 re-read 2 minutes ago

Ivabradine

Small molecule targets HCN4 via inhibition

Developed for
heart failure · coronary artery disorder · cardiogenic shock · infectious disease with sepsis · postural orthostatic tachycardia syndrome · atrial fibrillation · cardiovascular disorder · intermediate coronary syndrome
+24 more · long COVID-19 · persistent atrial fibrillation · systolic heart failure · acute subendocardial myocardial infarction · advanced heart failure · arterial disorder · autonomic nervous system disorder · cirrhotic cardiomyopathy · congestive heart failure · diabetic kidney disease · diastolic heart failure · dilated cardiomyopathy · hypertensive disorder · left ventricular failure · mitral valve stenosis · acute coronary syndrome · asthma · cardiac rhythm disease · chemotherapy-induced toxicity · chronic obstructive pulmonary disease · coronary atherosclerosis · migraine without aura · multiple organ dysfunction syndrome · myocardial disorder
Investigated by
Servier · Amgen · Ain Shams University · Bayside Health · Cairo University · Charite University, Berlin, Germany
+55 more · IRCCS San Raffaele · Kanecia Obie Zimmerman · University of Campania Luigi Vanvitelli · Adolfo Fontenla · Ahmed talaat ahmed aly · Alexandria University · Assistance Publique - Hôpitaux de Paris · Azienda Policlinico Umberto I · Baker Heart and Diabetes Institute · Bambino Gesù Hospital and Research Institute · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Carlos III Health Institute · Chun-Yao Huang · Col. Suthee Panichkul · Dana-Farber Cancer Institute · French National Institute of Health and Medical Research · Gødstrup Hospital · Hannover Medical School · Hospital Universitario Ramon y Cajal · Insel Gruppe AG, University Hospital Bern · Institute of Liver and Biliary Sciences, India · Jiangsu HengRui Medicine Co., Ltd. · Kocaeli University · Liverpool Heart and Chest Hospital NHS Foundation Trust · Mahidol University · Medical University of Warsaw · Ministero della Salute, Italy · Nanjing First Hospital, Nanjing Medical University · National Heart Institute, Egypt · National Institute of Cardiovascular Diseases, Pakistan · Phramongkutklao College of Medicine and Hospital · Policlinico Casilino ASL RMB · Post Graduate Institute of Medical Education and Research, Chandigarh · Qian geng · Sadat City University · Second Affiliated Hospital of Guangzhou Medical University · Spanish Clinical Research Network - SCReN · Stanford University · São Paulo Research Foundation · Tartu University Hospital · The Third Affiliated Hospital of Guangzhou Medical University · The University of Hong Kong · The Young Investigator Group of Cardiovascular Research · University Hospital Heidelberg · University Hospital Homburg/Saar · University Hospital, Essen · University Hospital, Geneva · University Hospital, Rouen · University of Calgary · University of California, San Diego · University of Maryland, Baltimore · University of Sao Paulo · Universitätsklinikum Leipzig · Xintong Pharmacy Company · Yale University

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) CORLANOR 2015-04-15 fda.gov
Approved EU (EMA) Corlentor 2005-10-25 europa.eu

Trials 56 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03987204 Jun → Sep 2019 persistent atrial fibrillation Yale University Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02236247 May 2013 → Jan 2017 heart failure University of Sao Paulo Unknown No outcome recorded
Phase 29 trials
Phase 2 NCT06305780 Mar 2024 → Jul 2025 long COVID-19 Kanecia Obie Zimmerman Completed No outcome recorded
Phase 2 NCT06305806 Mar 2024 → Oct 2025 long COVID-19 Kanecia Obie Zimmerman Completed No outcome recorded
Phase 2 NCT05141071 Nov 2021 → May 2022 infectious disease with sepsis Cairo University Completed No outcome recorded
Phase 2 NCT04580342 Oct 2020 → Jan 2021 hypotensive disorder Ahmed talaat ahmed aly Unknown No outcome recorded
Phase 2 NCT04405804 Jun 2020 → Jan 2021 dilated cardiomyopathy, heart failure Bambino Gesù Hospital and Research Institute Unknown No outcome recorded
Phase 2 NCT03137537 Feb 2018 → Nov 2020 autonomic nervous system disorder, lymphoma Dana-Farber Cancer Institute Terminated No outcome recorded
Phase 2 NCT02623569 Oct 2014 → Jun 2017 coronary artery disorder Xintong Pharmacy Company Unknown No outcome recorded
Phase 2 NCT00865917 Nov 2008 → Nov 2010 postural orthostatic tachycardia syndrome Hannover Medical School Unknown No outcome recorded
Phase 2 NCT00202579 Sep 2004 → Feb 2006 congestive heart failure Servier Completed No outcome recorded
Phase 2/33 trials
Phase 2/3 NCT07268170 Dec 2025 → Sep 2028 expected coronary artery disorder, ischemic disease Gødstrup Hospital Enrolling by invitation No outcome recorded
Phase 2/3 NCT04285736 Dec 2014 → May 2016 acute subendocardial myocardial infarction Cairo University Completed No outcome recorded
Phase 2/3 NCT02188082 May 2014 → Aug 2017 systolic heart failure Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 315 trials
Phase 3 NCT07714746 Apr 2026 → May 2027 expected cardiogenic shock National Institute of Cardiovascular Diseases, Pakistan Recruiting No outcome recorded
Phase 3 NCT05594342 Jul 2022 → Jan 2023 cardiogenic shock, heart failure, ischemic disease The Young Investigator Group of Cardiovascular Research Unknown No outcome recorded
Phase 3 NCT04031573 Feb 2021 → Feb 2026 overdue infectious disease with sepsis Assistance Publique - Hôpitaux de Paris Active not recruiting No outcome recorded
Phase 3 NCT03619187 Nov 2018 → Feb 2020 Amgen Withdrawn No outcome recorded
Phase 3 NCT03718273 Oct 2018 → Feb 2022 atrial fibrillation Adolfo Fontenla Completed No outcome recorded
Phase 3 NCT04308031 Aug 2018 → Dec 2020 atrial fibrillation, heart failure Chun-Yao Huang Unknown No outcome recorded
Phase 3 NCT03485482 Mar 2018 cardiovascular disorder Ain Shams University Completed No outcome recorded
Phase 3 NCT03182725 Feb 2018 → May 2020 postural orthostatic tachycardia syndrome University of California, San Diego Completed No outcome recorded
Phase 3 NCT03105219 Jul 2017 → May 2021 diabetic kidney disease Nanjing First Hospital, Nanjing Medical University Withdrawn No outcome recorded
Phase 3 NCT02584439 Dec 2015 → Jul 2019 arterial disorder University Hospital, Rouen Completed No outcome recorded
Phase 420 trials
Phase 4 NCT07135258 Oct 2025 → Oct 2027 expected persistent atrial fibrillation The University of Hong Kong Not yet recruiting No outcome recorded
Phase 4 NCT05882708 Jun 2023 → Dec 2026 expected infectious disease with sepsis Second Affiliated Hospital of Guangzhou Medical University Recruiting No outcome recorded
Phase 4 NCT06371222 Feb 2023 → Jan 2024 mitral valve stenosis Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Completed No outcome recorded
Phase 4 NCT05348057 Aug 2021 → Sep 2022 cardiovascular disorder Qian geng Unknown No outcome recorded
Phase 4 NCT05261464 Jan 2021 → Jun 2022 Mahidol University Unknown No outcome recorded
Phase 4 NCT04436016 Oct 2020 → Dec 2021 myocardial ischemia University Hospital, Geneva Completed No outcome recorded
Phase 4 NCT03631654 Oct 2020 → Aug 2021 advanced heart failure University of Maryland, Baltimore Withdrawn No outcome recorded
Phase 4 NCT03437369 May 2018 → Oct 2019 cardiogenic shock Hospital Universitario Ramon y Cajal Unknown No outcome recorded
Phase 4 NCT03456856 Sep 2017 → Apr 2019 systolic heart failure Amgen Completed No outcome recorded
Phase 4 NCT02507050 Mar 2016 coronary artery disorder Liverpool Heart and Chest Hospital NHS Foundation Trust Withdrawn No outcome recorded
Phase not applicable7 trials
NCT05636774 Dec 2022 → Jan 2025 University Hospital, Essen Completed No outcome recorded
NCT04881318 May 2021 → Dec 2026 expected postural orthostatic tachycardia syndrome University of Calgary Recruiting No outcome recorded
NCT04111133 Jan 2020 → Oct 2024 cirrhosis of liver, cirrhotic cardiomyopathy, portal hypertension Post Graduate Institute of Medical Education and Research, Chandigarh Unknown No outcome recorded
NCT04208594 Dec 2019 → May 2020 Alexandria University Unknown No outcome recorded
NCT03701880 Sep 2018 → Dec 2019 heart failure Ain Shams University Unknown No outcome recorded
NCT02294292 Jul 2014 → Aug 2016 diastolic heart failure, liver disorder Institute of Liver and Biliary Sciences, India Completed No outcome recorded
NCT01039389 Oct 2009 → Mar 2013 coronary artery disorder Insel Gruppe AG, University Hospital Bern Completed No outcome recorded
Also used as a comparator or background therapy in 32 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01804010 Comparator May → Sep 2007 Asan Medical Center Completed No outcome recorded
Phase 24 trials
Phase 2 NCT04186286 Comparator Feb 2021 → Dec 2025 overdue postural orthostatic tachycardia syndrome University of Calgary Recruiting No outcome recorded
Phase 2 NCT01761825 Comparator Dec 2012 → Feb 2013 postural orthostatic tachycardia syndrome Tel-Aviv Sourasky Medical Center Unknown No outcome recorded
Phase 2 NCT00757055 Comparator Dec 2012 → Nov 2013 diastolic heart failure St Vincent's University Hospital, Ireland Withdrawn No outcome recorded
Phase 2 NCT01186783 Comparator May 2010 → Nov 2011 multiple organ dysfunction syndrome Martin-Luther-University Halle-Wittenberg Unknown No outcome recorded
Phase 34 trials
Phase 3 NCT05279651 Comparator Jun 2022 → Apr 2025 overdue myocardial ischemia Jagiellonian University Active not recruiting No outcome recorded
Phase 3 NCT04030546 Comparator Jun 2019 → Jun 2020 Vilnius University Unknown No outcome recorded
Phase 3 NCT01657136 Comparator Sep 2013 → Sep 2016 cardiac rhythm disease Policlinico Casilino ASL RMB Completed No outcome recorded
Phase 3 NCT01022463 Comparator Nov 2009 → Oct 2010 mitral valve stenosis Govind Ballabh Pant Hospital Completed No outcome recorded
Phase 413 trials
Phase 4 NCT05481177 Comparator Jun 2023 → Sep 2024 long COVID-19, postural orthostatic tachycardia syndrome Uniformed Services University of the Health Sciences Unknown No outcome recorded
Phase 4 NCT04448899 Comparator Jun 2020 → Feb 2021 congestive heart failure Damanhour University Completed No outcome recorded
Phase 4 NCT03168529 Comparator Jul 2018 → Jul 2020 heart failure Phillip Levy Terminated No outcome recorded
Phase 4 NCT03405831 Comparator Apr 2018 → Dec 2019 Finn Gustafsson Unknown No outcome recorded
Phase 4 NCT03387605 Comparator Mar 2018 → Jan 2020 cardiac rhythm disease, cardiogenic shock, heart failure Loyola University Unknown No outcome recorded
Phase not applicable10 trials
NCT06742164 Comparator Dec 2024 → Jun 2025 overdue cardiac rhythm disease Ain Shams University Not yet recruiting No outcome recorded
NCT06670690 Comparator Sep 2023 Menoufia University Completed No outcome recorded
NCT06505668 Comparator Aug 2023 → Jun 2025 overdue cardiac rhythm disease, treatment-refractory schizophrenia All India Institute of Medical Sciences, Bhubaneswar Recruiting No outcome recorded
NCT04853797 Comparator May 2021 → Jul 2025 migraine without aura Danish Headache Center Completed No outcome recorded
NCT03650205 Comparator Jan 2019 → Oct 2021 chemotherapy-induced toxicity, heart failure, neoplasm University of Sao Paulo Unknown No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2015-04-15 Amgen FDA Approves Corlanor® (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure amgen.com

Evidence & citations 21 cited values

Every value below carries the sentence it was read from. 91 sources stand behind the page.

FieldValueCited text
Known as Ivabradine “Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin.” NCT05636774
87

“These medications include beta-blockers, midodrine, ivabradine and stimulants.” NCT04881318

NCT07135258

NCT02446990

NCT00757055

NCT00815100

NCT01029223

NCT01039389

NCT03137537

NCT03105219

NCT02046044

NCT04285736

NCT01657136

NCT02681978

NCT02188082

NCT01178528

NCT05594342

NCT01699776

NCT02294292

NCT04186286

NCT05261464

NCT03245996

NCT02623569

NCT06305806

NCT02584439

NCT04308031

NCT06305780

NCT01022463

NCT01364077

NCT03168529

NCT06371222

NCT01186783

NCT04405804

NCT03987204

NCT01768585

NCT02247245

NCT05279651

NCT02973594

NCT01425164

NCT03367026

NCT01755663

NCT03650205

NCT01761825

NCT02441218

NCT05348057

NCT06670690

NCT04448899

NCT03485482

NCT05481177

NCT01868880

NCT02827500

NCT01365286

NCT03437369

NCT07714746

NCT03456856

NCT06742164

NCT01804010

NCT07268170

NCT04111133

NCT00865917

NCT05141071

NCT02236247

NCT03387605

NCT03701880

NCT06505668

NCT03718273

NCT03619187

NCT00202566

NCT03405831

NCT01373619

NCT02354573

NCT05882708

NCT02086422

NCT04208594

NCT00825123

NCT04031573

NCT00202579

NCT00143507

NCT03830957

NCT04853797

NCT02507050

NCT04030546

NCT03182725

NCT03631654

NCT04436016

NCT03866395

NCT04580342

NCT02166060

Known as AMG 998 ChEMBL registry synonym — accepted as the source's own label CHEMBL471737
Known as Corlanor “Ivabradine 5 mg [Corlanor]” NCT04308031
Known as Corlentor ChEMBL registry synonym — accepted as the source's own label CHEMBL471737
Known as IVA Ivabradine (IVA) is a negative chronotropic agent without significant effects on contractility or vascular tone” NCT04436016
Known as ivabradin “single 10 mg oral dose of ivabradin (Procoralan®, Les Laboratoires Servier Industrie-France).” NCT03485482
Known as Ivabradina ChEMBL registry synonym — accepted as the source's own label CHEMBL471737
Known as Ivabradine accord ChEMBL registry synonym — accepted as the source's own label CHEMBL471737
Known as Ivabradine anpharm ChEMBL registry synonym — accepted as the source's own label CHEMBL471737
Known as Ivabradine hcl ChEMBL registry synonym — accepted as the source's own label CHEMBL471737
Known as IVABRADINE HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL471737
Known as Ivabradine jensonr ChEMBL registry synonym — accepted as the source's own label CHEMBL471737
Known as Ivabradine zentiva ChEMBL registry synonym — accepted as the source's own label CHEMBL471737
Known as Procoralan “single 10 mg oral dose of ivabradin (Procoralan®, Les Laboratoires Servier Industrie-France).” NCT03485482
2

“will receive oral ivabradine (Procoralan® 5mg manufactured by Servier laboratories, France)” NCT04208594

“Ivabradine (Procoralan)” NCT01365286

Known as Procoralen Procoralen is brand name for Ivabradine” NCT00757055
Known as S 16257 “To assess the pharmacokinetic profile of ivabradine (S 16257) and its main active metabolite S 18982 in Korean healthy volunteers after oral administration” NCT01804010
Known as S-16257-2 ChEMBL registry synonym — accepted as the source's own label CHEMBL471737
Action Inhibit “Ivabradine specifically inhibits the I(f) current in the sinoatrial node to lower heart rate” PMID 18757088 Aug 2008
Modality Small molecule CHEMBL471737
Route Oral Oral Administration of Ivabradine Compared to Placebo” NCT00202566
Target HCN4 “the HCN4 (hyperpolarization-activated cyclic nucleotide-gated potassium channel 4) channel inhibitor ivabradine” PMID 40052260 Mar 2025